TOP TEN perturbations for P06126 (Homo sapiens)

Organism: Homo sapiens
Gene: P06126
Selected probe(set): 210325_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P06126 (210325_at) across 5610 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):9.473849
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample

Relative Expression (log2-ratio):5.923978
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal myeloid dendritic cell sample
Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population.

human AB serum study 1 (late) / IL-4; GM-CSF study 1 (late)

Relative Expression (log2-ratio):-5.524441
Number of Samples:3 / 6
Experimental human AB serum study 1 (late)
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.

TNF-ɑ; IL-1b; IL-6; PGE2 study 1 / control antibody treated immature dendritic cell sample

Relative Expression (log2-ratio):-5.007889
Number of Samples:4 / 5
Experimental TNF-ɑ; IL-1b; IL-6; PGE2 study 1
Immature dendritic cells (DCs) treated with inflammatory cytokine cocktail (10 ng/ml IL-1b, 1,000 U/ml IL-6, 10 ng/ml TNF-ɑ, 1μg/ml prostaglandin E2) for 24 h.
Control control antibody treated immature dendritic cell sample
Immature dendritic cells (DCs) treated with isotype control antibody (10 - 20μg/ml mouse IgG1 isotype) for 24 h.

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):4.9545813
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-4.5652847
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-4.5571136
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):4.4576015
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

Langerhans cell histiocytosis study 3 / Langerhans cell histiocytosis study 4

Relative Expression (log2-ratio):4.230161
Number of Samples:10 / 7
Experimental Langerhans cell histiocytosis study 3
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease).
Control Langerhans cell histiocytosis study 4
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease).

Langerhans cell histiocytosis study 3 / normal tonsillar T-lymphocyte sample

Relative Expression (log2-ratio):3.9220629
Number of Samples:10 / 4
Experimental Langerhans cell histiocytosis study 3
CD3+ T-lymphocyte samples isolated from Langerhans cell histiocytosis (LCH) lesions in bone (8 cases) or skin (2 cases). Patient with different clinical status were included in this study (unifocal, single system; multifocal, single system and multifocal, multisystem disease).
Control normal tonsillar T-lymphocyte sample
Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue.